metaPreg - Topiramate (Epilepsy) during pregnancy

Topiramate (Epilepsy) updated on 04-22-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	2.07 [1.42, 3.04]	0%	10 studies	284	408	low	ROB	3.57 [2.18; .]
Major congenital malformations	2.07 [1.42, 3.04]	0%	10 studies	284	408	low	ROB	3.57 [2.18; .]
Congenital heart defects	2.75 [0.99, 7.59]	0%	4 studies	32	233	not evaluable	ROB	-
Limb defects	3.56 [0.59, 21.68]	0%	3 studies	5	81	not evaluable	ROB	-
Neural Tube Defects	5.56 [0.78, 39.78]	0%	3 studies	2	224	not evaluable	ROB	-
Digestive system anomalies	6.26 [0.69, 56.84]	0%	2 studies	4	37	not evaluable	ROB	-
Urinary malformations	1.68 [0.22, 13.11]	0%	2 studies	14	161	not evaluable	ROB	-
Hypospadias	3.30 [0.73, 14.97]	0%	2 studies	14	180	not evaluable	ROB	-
Oro-facial clefts	7.95 [0.83, 76.53]	19%	2 studies	5	180	not evaluable	ROB	-
5 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Small for gestational age (weight)	1.95 [1.40, 2.71]	52%	3 studies	2,469	684	not evaluable	ROB	3.31 [2.16; .]
Preterm (< 37 weeks)	0.75 [0.49, 1.16]	0%	2 studies	3	2	not evaluable	ROB	-
Low birth weight (< 2500g)	1.66 [1.05, 2.62]	-	1 study	1,027	290	not evaluable	ROB	2.71 [1.29; .]
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
3 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Intrauterine deaths (as a whole or unspecified)	13.39 [3.16, 56.70]	0%	4 studies	13	64	not evaluable	ROB	26.27 [5.78; .]
Late intrauterine deaths (> 22 weeks) / Stillbirths	15.37 [0.63, 376.77]	0%	2 studies		3	not evaluable	ROB	-
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions	8.47 [0.57, 125.19]	0%	2 studies	3	4	not evaluable	ROB	-
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
ASD (Autism spectrum disorder): Diagnosis/Risk	1.54 [0.85, 2.78]	37%	6 studies	790	1,034	not evaluable	ROB	-
ASD (Autism spectrum disorder): Diagnosis	1.52 [0.77, 3.00]	49%	5 studies	762	1,028	not evaluable	ROB	-
ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk	1.51 [0.89, 2.59]	28%	4 studies	582	431	not evaluable	ROB	-
Language disorders/delay	1.76 [0.63, 4.86]	0%	3 studies	43	36	not evaluable	ROB	-
ADHD (Attention deficit hyperactivity disorder): Diagnosis	1.82 [1.03, 3.23]	15%	3 studies	582	404	not evaluable	ROB	3.04 [1.19; .]
Cognitive developmental disorders/delay (> 6 years old)	3.32 [1.70, 6.47]	16%	3 studies	394	388	not evaluable	ROB	6.09 [2.79; .]
ASD (Autism spectrum disorder): Risk	2.65 [0.36, 19.38]	0%	2 studies	28	7	not evaluable	ROB	-
Neuro-developmental disorders (as a whole)	2.15 [1.15, 4.01]	0%	2 studies	455	248	not evaluable	ROB	3.72 [1.57; .]
Severe cognitive developmental delay (Mental retardation) (> 6 years old)	3.57 [1.42, 9.01]	52%	2 studies	388	361	not evaluable	ROB	6.60 [2.18; .]
Cognitive developmental disorders/delay (3-6 years old)	3.48 [1.46, 8.27]	0%	2 studies	13	289	not evaluable	ROB	6.41 [2.28; .]
Severe cognitive developmental delay (Mental retardation) (3-6 years old)	3.48 [1.46, 8.27]	0%	2 studies	13	289	not evaluable	ROB	6.41 [2.28; .]
3 non statistically significant endpoints reported in only one study